Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA) - Pipeline Review, H2 2016

  • ID: 3837866
  • Report
  • 42 pages
  • Global Markets Direct
1 of 6

FEATURED COMPANIES

  • Exicure, Inc.
  • Novartis AG
  • UCB S.A.
  • Vipergen ApS
  • MORE
Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA) - Pipeline Review, H2 2016

Summary

‘Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA) - Pipeline Review, H2 2016’, provides in depth analysis on Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA) targeted pipeline therapeutics.

The report provides comprehensive information on the Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA) targeted therapeutics development and features dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA)
- The report reviews Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA) targeted therapeutics and enlists all their major and minor projects
- The report assesses Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 6

FEATURED COMPANIES

  • Exicure, Inc.
  • Novartis AG
  • UCB S.A.
  • Vipergen ApS
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA) Overview

Therapeutics Development

Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA) - Products under Development by Stage of Development

Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA) - Products under Development by Therapy Area

Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA) - Products under Development by Indication

Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA) - Pipeline Products Glance

Late Stage Products

Early Stage Products

Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA) - Products under Development by Companies

Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA) - Therapeutics Assessment

Assessment by Monotherapy/Combination Products

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA) - Companies Involved in Therapeutics Development

Crescendo Biologics Limited

Exicure, Inc.

Novartis AG

Teva Pharmaceutical Industries Ltd.

UCB S.A.

Vipergen ApS

Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA) - Drug Profiles

Antisense Oligonucleotide to Antagonize IL-17RA for Inflammatory Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

bimekizumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CB-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

E-34935 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

E-35018 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

E-35762 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

E-36041 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Protein to Inhibit IL-17A for Psoriasis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize IL-17A for Inflammatory and Autoimmune Diseases - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA) - Dormant Projects

Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA) - Featured News & Press Releases

Jun 10, 2016: UCB’s bimekizumab demonstrates positive results in early development in patients with psoriatic arthritis

Jun 08, 2016: UCB presents Phase 1b data on Bimekizumab at the Annual European Congress of Rheumatology (EULAR 2016)

Sep 01, 2013: Vipergen presents first discovery of small molecule IL-17A antagonists

Apr 01, 2013: Ensemble Therapeutics To Present Preclinical Data On IL-17A Inhibitors At 245th ACS National Meeting

Nov 12, 2012: Ensemble Therapeutics Presents Oral Efficacy Of Small Molecule Targeting IL-17 For Inflammation In Preclinical Studies

Oct 29, 2012: Ensemble Therapeutics To Present Poster On Interleukin-17 At 2012 ACR Annual Meeting

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Number of Products under Development for, H2 2016

Number of Products under Development by Therapy Area, H2 2016

Number of Products under Development by Indication, H2 2016

Comparative Analysis by Late Stage Development, H2 2016

Comparative Analysis by Early Stage Products, H2 2016

Number of Products under Development by Companies, H2 2016

Products under Development by Companies, H2 2016

Assessment by Monotherapy/Combination Products, H2 2016

Number of Products by Stage and Mechanism of Action, H2 2016

Number of Products by Stage and Route of Administration, H2 2016

Number of Products by Stage and Molecule Type, H2 2016

Pipeline by Crescendo Biologics Limited, H2 2016

Pipeline by Exicure, Inc., H2 2016

Pipeline by Novartis AG, H2 2016

Pipeline by Teva Pharmaceutical Industries Ltd., H2 2016

Pipeline by UCB S.A., H2 2016

Pipeline by Vipergen ApS, H2 2016

Dormant Projects, H2 2016 36List of Figures

Number of Products under Development for, H2 2016

Number of Products under Development by Therapy Area, H2 2016

Number of Products under Development by Indication, H2 2016

Comparative Analysis by Early Stage Products, H2 2016

Assessment by Monotherapy/Combination Products, H2 2016

Number of Products by Stage and Mechanism of Actions, H2 2016

Number of Products by Routes of Administration, H2 2016

Number of Products by Stage and Routes of Administration, H2 2016

Number of Products by Molecule Types, H2 2016

Number of Products by Stage and Molecule Type, H2 2016
Note: Product cover images may vary from those shown
3 of 6

Loading
LOADING...

4 of 6

FEATURED COMPANIES

  • Exicure, Inc.
  • Novartis AG
  • UCB S.A.
  • Vipergen ApS
  • MORE
According to our recently published report 'Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA) – Pipeline Review, H2 2016'; Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA) pipeline Target constitutes close to 9 molecules. Out of which approximately 9 molecules are developed by Companies.

Furthermore, the publisher says: Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA) Interleukin 17 receptor A is a cytokine receptor for IL17A. Activation of IL17RA leads to induction of expression of inflammatory chemokines and cytokines such as CXCL1, CXCL8/IL8 and IL6.

The report 'Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA) – Pipeline Review, H2 2016' outlays comprehensive information on the Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA) targeted therapeutics development, features dormant and discontinued projects and latest news and press releases. Currently, The molecules developed by Companies in Phase II, Preclinical and Discovery stages are 1, 6 and 2 respectively.
Note: Product cover images may vary from those shown
5 of 6
Crescendo Biologics Limited
Exicure, Inc.
Novartis AG
Teva Pharmaceutical Industries Ltd.
UCB S.A.
Vipergen ApS
Note: Product cover images may vary from those shown
6 of 6
Note: Product cover images may vary from those shown
Adroll
adroll